Free Trial

Indivior (INDV) Competitors

Indivior logo
$25.28 +0.38 (+1.53%)
Closing price 10/23/2025 04:00 PM Eastern
Extended Trading
$25.84 +0.56 (+2.22%)
As of 10/23/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INDV vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

Indivior vs. Its Competitors

Indivior (NASDAQ:INDV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

In the previous week, 180 Life Sciences had 1 more articles in the media than Indivior. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Indivior. Indivior's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score.

Company Overall Sentiment
Indivior Neutral
180 Life Sciences Neutral

60.3% of Indivior shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indivior currently has a consensus price target of $22.00, suggesting a potential downside of 12.97%. Given Indivior's stronger consensus rating and higher probable upside, research analysts clearly believe Indivior is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Indivior has higher revenue and earnings than 180 Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior$1.19BN/A$2M$0.6240.77
180 Life SciencesN/AN/AN/AN/AN/A

Indivior has a net margin of 6.65% compared to 180 Life Sciences' net margin of 0.00%. 180 Life Sciences' return on equity of 0.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior6.65% -86.28% 16.26%
180 Life Sciences N/A N/A N/A

Summary

Indivior beats 180 Life Sciences on 8 of the 10 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDV vs. The Competition

MetricIndiviorMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.63B$6.19B$10.59B
Dividend YieldN/A57.75%5.72%4.86%
P/E Ratio40.7723.9429.6728.46
Price / SalesN/A777.91575.20225.64
Price / Cash13.68165.1936.5560.64
Price / Book-10.035.5712.076.53
Net Income$2M$33.06M$3.32B$276.75M
7 Day Performance3.27%2.10%0.64%0.93%
1 Month Performance10.63%5.91%5.17%1.41%
1 Year Performance188.26%-2.82%61.77%31.59%

Indivior Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDV
Indivior
1.7873 of 5 stars
$25.28
+1.5%
$22.00
-13.0%
+195.3%$0.00$1.19B40.771,051Upcoming Earnings
ATNFW
180 Life Sciences
N/A$0.06
-11.2%
N/A+264.5%$0.00N/A0.007
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AIMDW
Ainos
N/A$0.21
-22.2%
N/AN/A$0.00$110.87K0.0040Positive News
Gap Up
ALVOW
Alvotech
N/A$1.50
-14.3%
N/A-39.3%$0.00$560.10M0.004Positive News
Gap Up
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
flat
N/A-47.8%$0.00N/A0.0015Gap Up
BFRIW
Biofrontera
N/A$0.10
-3.9%
N/A+224.0%$0.00$39.19M0.0070Positive News
BTMDW
biote
N/A$0.01
-15.8%
N/A-97.8%$0.00$199.07M0.00N/AGap Down
High Trading Volume
BCTXW
BriaCell Therapeutics
N/A$0.06
-4.8%
N/A-83.1%$0.00N/A0.008Gap Down
High Trading Volume
CELUW
Celularity
N/A$0.04
+5.4%
N/AN/A$0.00$44.59M0.00220Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:INDV) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners